PAP
ALNY icon

Persistent Asset Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Persistent Asset Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46
Closed -$43K – 181
2025
Q1 		$43K Buy
+46
New +$11.8K 0.04% 136

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Persistent Asset Partners's ALNY Position: Q1 2026 in Review

Persistent Asset Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,433 shares — an estimated $570K sold.

Persistent Asset Partners first reported a position in ALNY in Q1 2025 and held it in 3 quarters. The position peaked at $1.03M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Persistent Asset Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 1,433 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $570K.
  • Persistent Asset Partners first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Persistent Asset Partners's Alnylam Pharmaceuticals position peaked at $1.03M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.